Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients

A phase II study

F. Perrone, S. De Placido, C. Carlomagno, A. Gravina, M. De Laurentiis, L. Del Mastro, C. Gridelli, C. Pagliarulo, A. R. Bianco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle. All patients were evaluated for toxicity and response. Overall, 83 cycles were administered, with a median number of 4 cycles per patient. Hematologic toxicity, not requiring hospitalization, was the major side effect. Vomiting occurred in 19.2% of cycles. Objective response rate was 33.3% (95% confidence interval: 12.2-53.1%): best responses were 1 complete and 6 partial; also 7 stable and 7 progressive disease were recorded. The best responding site was the viscera, the worst was bone. Responses were seen preferentially in second- rather than in third-line therapy and in patients who had responded to previous chemotherapy, although differences were not statistically significant. Kaplan-Meier estimated median time to progression and overall survival were 26 weeks (range: 2-67 weeks) and 35 weeks (range: 6-79 weeks), respectively. In conclusion the MM regimen showed acceptable toxicity and appreciable activity in anthracycline- pretreated advanced breast cancer.

Original languageEnglish
Pages (from-to)218-222
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number3
Publication statusPublished - 1994

Fingerprint

Mitoxantrone
Anthracyclines
Mitomycin
Breast Neoplasms
Viscera
Vomiting
Hospitalization
Confidence Intervals
Bone and Bones
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients : A phase II study. / Perrone, F.; De Placido, S.; Carlomagno, C.; Gravina, A.; De Laurentiis, M.; Del Mastro, L.; Gridelli, C.; Pagliarulo, C.; Bianco, A. R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 3, 1994, p. 218-222.

Research output: Contribution to journalArticle

@article{8670af7688cf4b418e3864f9381444b9,
title = "Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients: A phase II study",
abstract = "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle. All patients were evaluated for toxicity and response. Overall, 83 cycles were administered, with a median number of 4 cycles per patient. Hematologic toxicity, not requiring hospitalization, was the major side effect. Vomiting occurred in 19.2{\%} of cycles. Objective response rate was 33.3{\%} (95{\%} confidence interval: 12.2-53.1{\%}): best responses were 1 complete and 6 partial; also 7 stable and 7 progressive disease were recorded. The best responding site was the viscera, the worst was bone. Responses were seen preferentially in second- rather than in third-line therapy and in patients who had responded to previous chemotherapy, although differences were not statistically significant. Kaplan-Meier estimated median time to progression and overall survival were 26 weeks (range: 2-67 weeks) and 35 weeks (range: 6-79 weeks), respectively. In conclusion the MM regimen showed acceptable toxicity and appreciable activity in anthracycline- pretreated advanced breast cancer.",
author = "F. Perrone and {De Placido}, S. and C. Carlomagno and A. Gravina and {De Laurentiis}, M. and {Del Mastro}, L. and C. Gridelli and C. Pagliarulo and Bianco, {A. R.}",
year = "1994",
language = "English",
volume = "17",
pages = "218--222",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients

T2 - A phase II study

AU - Perrone, F.

AU - De Placido, S.

AU - Carlomagno, C.

AU - Gravina, A.

AU - De Laurentiis, M.

AU - Del Mastro, L.

AU - Gridelli, C.

AU - Pagliarulo, C.

AU - Bianco, A. R.

PY - 1994

Y1 - 1994

N2 - Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle. All patients were evaluated for toxicity and response. Overall, 83 cycles were administered, with a median number of 4 cycles per patient. Hematologic toxicity, not requiring hospitalization, was the major side effect. Vomiting occurred in 19.2% of cycles. Objective response rate was 33.3% (95% confidence interval: 12.2-53.1%): best responses were 1 complete and 6 partial; also 7 stable and 7 progressive disease were recorded. The best responding site was the viscera, the worst was bone. Responses were seen preferentially in second- rather than in third-line therapy and in patients who had responded to previous chemotherapy, although differences were not statistically significant. Kaplan-Meier estimated median time to progression and overall survival were 26 weeks (range: 2-67 weeks) and 35 weeks (range: 6-79 weeks), respectively. In conclusion the MM regimen showed acceptable toxicity and appreciable activity in anthracycline- pretreated advanced breast cancer.

AB - Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle. All patients were evaluated for toxicity and response. Overall, 83 cycles were administered, with a median number of 4 cycles per patient. Hematologic toxicity, not requiring hospitalization, was the major side effect. Vomiting occurred in 19.2% of cycles. Objective response rate was 33.3% (95% confidence interval: 12.2-53.1%): best responses were 1 complete and 6 partial; also 7 stable and 7 progressive disease were recorded. The best responding site was the viscera, the worst was bone. Responses were seen preferentially in second- rather than in third-line therapy and in patients who had responded to previous chemotherapy, although differences were not statistically significant. Kaplan-Meier estimated median time to progression and overall survival were 26 weeks (range: 2-67 weeks) and 35 weeks (range: 6-79 weeks), respectively. In conclusion the MM regimen showed acceptable toxicity and appreciable activity in anthracycline- pretreated advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028223425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028223425&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 218

EP - 222

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -